A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

Memorial Hospital Central
Memorial Hospital North

Principal Investigator
Photograph of Robert Hoyer

Robert Hoyer

Study ID

Protocol Number: 22-2095

More information available at ClinicalTrials.gov: NCT05555732

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers